Interim report
Page 1
INTERIM REPORT – Q2 2026 #01 ASKER HEALTHCARE GROUP FINANCIAL STATEMENTS DEFINITIONS ABOUT ASKERFINANCIAL OVERVIEW START CEO’S COMMENTS Key performance indicators 1 April–30 June 1 January–30 June Rolling 12 months Full-year Amounts in SEKm, unless otherwise stated 2026 2025 Change 2026 2025 Change 2025/2026 2025 Net sales 4,686 3,987 18% 9,207 7,982 15% 18,012 16,787 Adjusted EBITA* 471 378 24% 912 742 23% 1,765 1,594 Adjusted EBITA margin, %* 10.0% 9.5% 0.5 p.p. 9.9% 9.3% 0.6 p.p. 9.8% 9.5% EBITA* 475 323 47% 903 634 42% 1,659 1,390 EBITA margin, %* 10.1% 8.1% 2 p.p. 9.8% 7.9% 1.9 p.p. 9.2% 8.3% EBIT 349 249 40% 659 487 35% 1,181 1,009 Profit for the period 225 133 70% 422 228 85% 704 510 Earnings per share before and after dilution (SEK) 0.57 0.34 70% 1.07 0.54 101% 1.78 1.25 Earnings per share before and after dilution (SEK), adjusted* 0.57 0.34 70% 1.07 0.57 87% 1.78 1.28 Net debt/EBITDA** 2.37 1.84 0.53x 2.37 1.84 0.53x 2.37 2.26 Return on net working capital (EBITA/NWC), %* 68.7% 65.4% 3.4 p.p. 68.7% 65.4% 3.4 p.p. 68.7% 67.0% Adjusted cash flow from operating activities* 330 211 57% 749 320 134% 1,814 1,385 * Refer to Note 5 for the calculation of alternative performance measures and the definitions section for further information about these performance indicators. ** EBITDA rolling 12 months adjusted for leases and items affecting comparability. 1 April–30 June 2026 • Net sales amounted to SEK 4,686m (3,987), up 18%. • Adjusted EBITA amounted to SEK 471m (378), up 24%. • The adjusted EBITA margin amounted to 10.0% (9.5). • EBIT amounted to SEK 349m (249), and profit for the quarter amounted to SEK 225m (133). • Earnings per share before and after dilution amounted to SEK 0.57 (0.34). • Return on net working capital (EBITA/NWC) amounted to 68.7% (65.4). • Adjusted cash flow from operating activities amounted to SEK 330m (211). 1 January–30 June 2026 • Net sales amounted to SEK 9,207m (7,982), up 15%. • Adjusted EBITA amounted to SEK 912m (742), up 23%. • The adjusted EBITA margin was 9.9% (9.3). • EBIT amounted to SEK 659m (487), and profit for the period amounted to SEK 422m (228). • Earnings per share before and after dilution amounted to SEK 1.07 (0.54). • Return on net working capital (EBITA/NWC) amounted to 68.7% (65.4). • Adjusted cash flow from operating activities amounted to SEK 749m (320). Steady growth that continues to outperform the market, with strong earnings leverage supported by the Group’s increased scale. The adjusted EBITA margin increased to 10.0%. One new acquisition signed, and continued good visibility among many high-quality acquisition candidates. Interim Report January–June 2026 Q2
Page 2
INTERIM REPORT – Q2 2026 #02 ASKER HEALTHCARE GROUP START CEO’S COMMENTS FINANCIAL STATEMENTS DEFINITIONS ABOUT ASKERFINANCIAL OVERVIEW capacity to meet high environmental standards and maintain effective control over the value chain playing a crucial role in winning contracts. In April, Asker was also awarded the highest rating, AAA, in the MSCI ESG Rating’s first review of the company, an achieve- ment we are very proud of. Past halfway to our acquisition target for the year In early July, we completed another acquisition, Murray Surgi- cal, which strengthens and is a good complement to the HSL Group in surgical and medical products in Ireland. Discontinuing an acquisition process is sometimes the right thing to do. After a long closing process, we agreed with the seller in the spring to terminate the acquisition of Kirstine Hardam. Instead, we are turning our focus to the other many attractive opportunities in our pipeline. We continue to have good acquisition pipeline visibility. Our target is to complete acquisitions each year that contribute 10–12% to our EBITA growth. Now that six months of the year have passed, we have come more than halfway to achieving this acquisition target while also strengthening the Group’s EBITA margin. Value-generating growth over time Our priority is to continue growing Asker through regular strategic acquisitions, decentralised accountability, gradual realisation of benefits from our enhanced capacity and market presence, and maintaining a focus on cash flow and capital efficiency. By combining entrepreneur- ship and close proximity to customers with Asker’s growing scale, we are creating a platform to continue driving prog- ress in the healthcare sector and delivering on our financial targets. Johan Falk, CEO Continued steady growth All business areas report good growth Organic growth remained favourable, driven once again this quarter by many small but varied advances within the compa- nies, combined with Asker’s increased scale and reach. We once again delivered overall earnings growth well above our financial target, clearly supported by Asker’s active acquisition agenda over the past year. I am also pleased to see that the acquisitions made to date this year have started well. Business Area North continued to grow organically, noting healthy profitability and stable margins. The move to and startup of the new warehouse in Gothenburg are proceeding according to plan, with the facility expecting to be fully opera- tional by the end of the year. Business Area West delivered another quarter of good earnings growth, underpinned by completed acquisitions and economies of scale from its growing home care operations. Earnings continued to strengthen for Business Area Central, which reported a positive margin trend, driven primarily by completed acquisitions and an improved product mix. The adjusted EBITA margin increased to 10.0% (9.5) for the Group as a whole. Stability that provides flexibility Steady demand for medical products in the healthcare sector provides a solid foundation for our business. This builds resilience across business cycles when combined with Asker’s increased scale, geographic footprint and progressively broader product portfolio. Steady demand generates consistent operating cash flows, in turn giving us the flexibility to complete acquisitions and invest in more efficient solutions, such as new warehouses. During the quarter, we maintained a stable leverage and good acquisition capacity, while paying a dividend as well as larger-than-usual contingent considerations due to the strong performance of the companies. Sustainability initiatives drive business Our long-term sustainability initiatives aimed at ensuring a fair and sustainable value chain make a tangible contribution to our business. Our ESG investments of recent years have made a clear difference in various procurement processes, with our During the second quarter, our organic growth continued to outperform the market, and we reported a 5% increase in sales and a 6% increase in adjusted EBITA. In parallel, we took further steps to broaden our product portfolio and strengthen our position in Europe, signing a new acquisition agreement in early July. In total, sales increased by 18% during the quarter, and adjusted EBITA by 24%. The adjusted EBITA margin strengthened to 10.0%. Continued healthy and stable cash flows. Efficient capital utilisation supported an increase in EBITA/NWC to 69%. CEO’S COMMENTS
Page 3
#03 ASKER HEALTHCARE GROUP INTERIM REPORT – Q2 2026 START CEO’S COMMENTS FINANCIAL STATEMENTS DEFINITIONS ABOUT ASKER FINANCIAL OVERVIEW Financial performance – Group Net sales Net sales for the second quarter amounted to SEK 4,686m (3,987), up 18% year-on- year, of which 5% was organic growth and 13% from acquisitions. Sales growth was driven by a favourable organic performance and the completion of acquisitions in the Business Areas West and Central. Net sales in the January-June period amounted to SEK 9,207m (7,982), up 15%, of which 5% was organic growth and 12% from acquisitions, while exchange rates had a negative impact of –2%. Adjusted EBITA, net financial items and profit for the period Adjusted EBITA for the second quarter amounted to SEK 471m (378), up 24%, of which 6% was organic growth and 18% from acquisitions. Adjusted EBITA in the January-June period amounted to SEK 912m (742), up 23%, of which 7% was organic growth and 18% from acquisitions, while exchange rates had a negative impact of –2%. Growth was driv- en by sales growth and improved margins in established and newly acquired companies. The adjusted EBITA margin was 10.0% (9.5) for the second quarter and 9.9% (9.3) for the period. Operating profit (EBIT) amounted to SEK 349m (249) for the second quarter and to SEK 659m (487) for the January-June period. Net financial items amounted to SEK –65m (–77) for the second quarter and to SEK –118m (–181) for the January-June period. The lower net financial expense compared with the preceding year is primarily the result of unrealised foreign exchange rate gains on loans and derivatives, respectively. Tax amounted to SEK –59m (–39) for the second quarter and to SEK –119m (–78) for the January-June period, yielding an effective tax rate of 21% (23) for the quarter and 22% (25) for the period. Profit for the period amounted to SEK 225m (133) in the second quarter and to SEK 422m (228) for the January-June period. Financial position and cash flow Adjusted cash flow from operating activities amounted to SEK 330m (211) for the second quarter and to SEK 749m (320) for the January-June period. The increased cash flow for the quarter was primarily the result of favourable earnings growth and efficient working capital management. Furthermore, scheduled payments totalling SEK 463m were made during the quarter for contingent considerations, of which SEK 238m impacted cash flow from operating activities and SEK 226m impacted cash flow from investing activities. The contingent considerations paid were primarily attributable to acquisitions completed in 2022 and 2023, which fell due for payment at the end of 2025. During the quarter, the dividend of SEK 149m resolved on by the Annual General Meeting was also paid. Net debt increased to SEK 4,511m (2,886). Net debt in relation to adjusted EBITDA amounted to 2.37 (1.84). Return on net working capital (EBITA/NWC) increased to 68.7% (65.4). At the end of the quarter, cash and cash equivalents amount- ed to SEK 777m (1,325) and undrawn credit facilities to SEK 569m (657). Items affecting comparability Items affecting comparability amounted to SEK –4m (55) for the second quarter, of which SEK 9m (15) was related to acquisition and integration expenses, SEK –17m (39) to revaluations of contingent considerations, and SEK 3m (1) to other items af- fecting comparability. Items affecting comparability amounted to SEK 9m (108) for the January-June period, of which SEK 20m (37) was related to acquisition and integration expenses, SEK –14m (56) to revaluations of contingent considerations, and SEK 4m (15) to other items affecting comparability, with the year-on-year difference attributable to items affecting comparability related to the IPO in 2025. Adjusted EBITA per quarter SEKm Adjusted EBITA-margin % Adjusted EBITA 20252024 2026 0 100 200 300 400 500 Q2Q1Q4Q3Q2Q1Q4Q3Q2 0 2 4 6 8 10 Net sales per quarter SEKm 20252024 2026 0 1,000 2,000 3,000 4,000 5,000 Q2Q1Q4Q3Q2Q1Q4Q3Q2 Adjusted EBITA growth Jan–Jun 2026 % 7% 23% 18% –2% 0 5 10 15 20 25 Total growth Exchange rate effect Acquired growth Organic growth
Page 4
#04 ASKER HEALTHCARE GROUP INTERIM REPORT – Q2 2026 START CEO’S COMMENTS FINANCIAL STATEMENTS DEFINITIONS ABOUT ASKER FINANCIAL OVERVIEW Earnings per share Profit for the period attributable to the Parent Company’s shareholders amounted to SEK 219m (129) for the second quarter and to SEK 412m (220) for the period. Earnings per share, before and after dilution, amounted to SEK 0.57 (0.34) for the second quarter and SEK 1.07 (0.54) for the period. The average number of common shares outstanding, before and after dilution, used in the calculation of earnings per share was 383,036,497 for both the second quarter and the period, and 383,036,497 for the second quarter of 2025 and 353,294,482 for the period in 2025. Refer to Note 5 for a reconciliation and calculation. At the end of the period, the number of common shares outstanding totalled 383,036,497. * EBITDA rolling 12 months adjusted for expenses attributable to leases and items affecting comparability. Financial targets and rolling 12-month outcomes TARGET >15% Adjusted EBITA growth per year OUTCOME +21% TARGET >10% Adjusted EBITA margin (medium term) OUTCOME 9.8% TARGET >50% Return on net working capital, EBITA/NWC OUTCOME 69% TARGET <2.5x Net debt/ EBITDA* OUTCOME 2.37x Dividend policy TARGET >30% OUTCOME 0.39 SEK/SHARE (corresponding to 30%) Progress towards 2030 sustainability targets is on track STATUS AS PER 2025 –22% ON TRACK Reduced Scope 1 and 2 emissions* STATUS AS PER 2025 –40% ON TRACK Reduced Scope 3 emissions** STATUS AS PER 2025 85% ON TRACK Code of Conduct for suppliers*** * Reduced Scope 1 and 2 emissions as a percentage compared to the 2021 base year, market-based. ** Total Scope 3, category 1 emissions per SEK m gross profit (tCO2e/SEKm). *** Percentage of suppliers, based on sales, that have signed Asker’s Code of Conduct or an equivalent code. For all sustainability targets, refer to the 2025 Annual Report. TARGET 2030 –42% TARGET 2030 –52% TARGET 2030 >90%
Page 5
#05 ASKER HEALTHCARE GROUP INTERIM REPORT – Q2 2026 START CEO’S COMMENTS FINANCIAL STATEMENTS DEFINITIONS ABOUT ASKER FINANCIAL OVERVIEW Financial performance – Business areas Asker Healthcare Group focuses on northern, western and central Europe and currently has a presence in 19 countries. The Group also has a quality and audit office in Asia. The Group’s operations are conducted in three business areas defined by geographical market, comprising North, West and Central. North consists of Sweden, Norway, Finland, Estonia, Latvia and Lithuania. Operations are conducted through 18 subsidiaries. The average number of full-time equivalents during the period was 894 (784). Financial performance Net sales in the second quarter amounted to SEK 1,429m (1,265), up 13%, of which 10% was organic growth and 2% from acquisitions, while exchange rates had a positive impact of 1%. Adjusted EBITA for the second quarter amounted to SEK 193m (175), up 10%, and the adjusted EBITA margin amounted to 13.5% (13.9). Net sales for the January–June period amounted to SEK 2,783m (2,527), up 10%, of which 8% was organic growth and 2% from acquisitions. Adjusted EBITA for the January–June period amounted to SEK 379m (352), up 8%, and the adjusted EBITA margin amounted to 13.6% (13.9). Operations in North continued to generate favourable organic growth during both the quarter and the first half of 2026, maintaining margins above 13% over the past 12 months. Work on the new distribution centre in Gothenburg proceeded according to plan. Testing and a gradual move to the new warehouse are underway, with efforts set to intensify in the autumn. 1 April–30 June 1 January–30 June Rolling 12 months Full-year Amounts in SEKm 2026 2025 Change 2026 2025 Change 2025/2026 2025 Net sales 1,429 1,265 13% 2,783 2,527 10% 5,465 5,210 Adjusted EBITA 193 175 10% 379 352 8% 708 681 Adjusted EBITA margin, % 13.5% 13.9% –0.4 p.p. 13.6% 13.9% –0.3 p.p. 13.0% 13.1% 0 1 2 3 4 5 6 7 8 Total growth Exchange rate effect Acquired growth Organic growth Adjusted EBITA growth – North Jan–Jun 2026 % 0%3% 5% 8% Business Area North Net sales per segment, LTM, 1 July 2025 – 30 June 2026 North West Central 30% 51% 19%
Page 6
#06 ASKER HEALTHCARE GROUP INTERIM REPORT – Q2 2026 START CEO’S COMMENTS FINANCIAL STATEMENTS DEFINITIONS ABOUT ASKER FINANCIAL OVERVIEW Business Area West Adjusted EBITA growth – West Jan–Jun 2026 % 0 5 10 15 20 25 30 35 Total growth Exchange rate effect Acquired growth Organic growth 32% –3% 12% 23% West consists of the Netherlands, Belgium, Luxembourg, the UK, Ireland and Denmark. Operations are conducted through 18 subsidiaries. The average number of full-time equivalents during the period was 2,107 (1,972). Financial performance Net sales in the second quarter amounted to SEK 2,327m (2,021), up 15%, of which 2% was organic growth and 14% from acquisitions, while exchange rates had a negative impact of –1%. Adjusted EBITA for the second quarter amounted to SEK 224m (169), up 32%, and the adjusted EBITA margin amounted to 9.6% (8.4). Net sales in the January–June period amounted to SEK 4,580m (4,029), up 14%, of which 4% was organic growth and 13% from acquisitions, while exchange rates had a negative impact of –3%. Adjusted EBITA for the January–June period amounted to SEK 438m (330), up 32%, and the adjusted EBITA margin amounted to 9.6% (8.2). The business area continued to consistently improve its sales and margins, driven by economies of scale and an expanded product and service offering. New acquisitions made a strong contribution from start, and the July acquisition of the Irish company Murray Surgical will further complement the product offering in the region. 1 April–30 June 1 January–30 June Rolling 12 months Full-year Amounts in SEKm 2026 2025 Change 2026 2025 Change 2025/2026 2025 Net sales 2,327 2,021 15% 4,580 4,029 14% 9,095 8,543 Adjusted EBITA 224 169 32% 438 330 32% 864 757 Adjusted EBITA margin, % 9.6% 8.4% 1.2 p.p. 9.6% 8.2% 1.4 p.p. 9.5% 8.9%
Page 7
#07 ASKER HEALTHCARE GROUP INTERIM REPORT – Q2 2026 START CEO’S COMMENTS FINANCIAL STATEMENTS DEFINITIONS ABOUT ASKER FINANCIAL OVERVIEW Business Area Central Central consists of France, Germany, Austria, Switzerland, Slovakia, Poland and the Czech Republic. Operations are conducted through 18 subsidiaries. The average number of full-time equivalents during the period was 1,003 (760). Financial performance Net sales for the second quarter amounted to SEK 931m (701), up 33%, of which 2% was organic and 31% from acquisitions. Adjusted EBITA for the second quarter amounted to SEK 90m (57), up 56%, and the adjusted EBITA margin amounted to 9.6% (8.2). Net sales in the January–June period amounted to SEK 1,844m (1,426), up 29%, of which 3% was organic growth and 28% from acquisitions, while exchange rates had a negative impact of –2%. Adjusted EBITA for the for the January–June period amounted to SEK 170m (112), up 52%, and the adjusted EBITA margin amounted to 9.2% (7.8). Acquisitions made over the past year complemented the business area’s organic growth and supported the strong growth performance of recent quarters. The focus on margin-enhancing activities continued to generate positive results during the quarter. 0 10 20 30 40 50 60 Total growth Exchange rate effect Acquired growth Organic growth Adjusted EBITA growth – Central Jan–Jun 2026 % 14% 52% –2% 40% 1 April–30 June 1 January–30 June Rolling 12 months Full-year Amounts in SEKm 2026 2025 Change 2026 2025 Change 2025/2026 2025 Net sales 931 701 33% 1,844 1,426 29% 3,452 3,034 Adjusted EBITA 90 57 56% 170 112 52% 316 259 Adjusted EBITA margin, % 9.6% 8.2% 1.4 p.p. 9.2% 7.8% 1.4 p.p. 9.2% 8.5%
Page 8
#08 ASKER HEALTHCARE GROUP INTERIM REPORT – Q2 2026 START CEO’S COMMENTS FINANCIAL STATEMENTS DEFINITIONS ABOUT ASKER FINANCIAL OVERVIEW Employees During the period, full-time equivalents in the Group averaged 4,053 (3,560), of which the Group function had 49 (44) full- time equivalents. The number of employees was 4,885 at the end of the period (4,248) and 4,559 at the start of the period. Parent Company Asker Healthcare Group AB (559184-9848) is the Parent Company of the Group. Net sales for the Parent Company amounted to SEK 8m (7) for the second quarter. Net financial items amounted to SEK –3m (–8) and loss before tax was SEK –6m (–20). Total assets amounted to SEK 7,607m (7,814) and total liabilities to SEK 3,282m (3,302). The Parent Company has 2 (2) employees. Accounting policies This interim report has been prepared in accordance with IAS 34 Interim Financial Reporting, the Swedish Corporate Report- ing Board’s recommendation RFR 1 and the Swedish Annual Accounts Act. The information submitted in accordance with IAS 34.16A has been presented both in the consolidated finan- cial statements and in other sections of this interim report. The interim report is presented in million Swedish kronor (SEKm) unless otherwise stated. Amounts in parenthesis refer to the preceding year. There may be differences in totals since indi- vidual items have been rounded to the nearest whole SEKm. The accounting policies have been applied as described in the Group’s 2025 Annual Report. None of the amendments to IFRS Accounting Standards that entered force during the year had any material impact on the consolidated financial statements. For more information, refer to the disclosures as described in the Group’s 2025 Annual Report. The Parent Company’s financial statements have been pre- pared in accordance with the Swedish Corporate Reporting Board’s recommendation RFR 2 Accounting for Legal Entities and the Swedish Annual Accounts Act. RFR 2 means that the Parent Company for the legal entity is to apply all IFRS accounting standards and statements as adopted by the EU as far as possible within the framework of the Annual Accounts Act and taking into account the relationship between account- ing and taxation. Other information Estimates and judgments There have been no changes in the estimates and judgments described in the Group’s most recently issued Annual Report for 2025. Related-party transactions No material transactions with related parties were conducted during the quarter. For further information on related-party transactions, refer to the Group’s Annual Report. Material risks and uncertainties The Group’s strategic and operational position, and the expected trend in its earnings and financial position, may be affected by risks and uncertainties that the Group is exposed to. Asker works continuously to identify and monitor risks so that it can leverage opportunities to achieve business targets or counter- act such risks that the Group is unwilling to take. The material risks that are deemed to have the greatest impact on the Group are strategic and operational risks related to geopolitics and disruptions to the global supply chain, IT and information security-related risks and financial stability. In addition, the Group is impacted by financial risks such as currency risks, liquidity risks and refinancing risks. Changes to risk during the quarter The general uncertainty in global markets remains high. Company management is closely following developments and mitigation plans are followed up and adjusted as necessary. Increasing geopolitical unrest could disrupt supply chains, but the geopolitical situation did not impact the Group’s financial position during the quarter. For more information on the Group’s risks, refer to the risk section in the Group’s Annual Report for 2025.
Page 9
#09 ASKER HEALTHCARE GROUP INTERIM REPORT – Q2 2026 START CEO’S COMMENTS FINANCIAL STATEMENTS DEFINITIONS ABOUT ASKER FINANCIAL OVERVIEW The Board of Directors and the CEO give their assurance that this interim report provides a true and fair overview of the operations, financial position and earnings of the Parent Company and of the Group, and describes material risks and uncertainties faced by the Parent Company and the companies that form the Group. The content of the interim report was approved on 20 July 2026. Danderyd, 21 July 2026 Asker Healthcare Group AB Mikael Stöhr Chairman of the Board Nina Linander Board member Karl Petersson Board member Birgitta Stymne Göransson Board member Mikael Vinje Board member Joachim Zetterlund Board member Johan Falk CEO This report has not been reviewed by Asker Healthcare Group’s auditors.
Page 10
#10 ASKER HEALTHCARE GROUP INTERIM REPORT – Q2 2026 START CEO’S COMMENTS FINANCIAL STATEMENTS DEFINITIONS ABOUT ASKER FINANCIAL OVERVIEW Financial statements – Group Consolidated income statement 1 April–30 June 1 January–30 June Full-year Amounts in SEKm Note 2026 2025 2026 2025 2025 Net sales 2 4,686 3,987 9,207 7,982 16,787 Cost of goods sold –2,721 –2,357 –5,377 –4,723 –9,916 Gross profit 1,966 1,630 3,830 3,259 6,871 Selling expenses –1,139 –968 –2,232 –1,937 –4,119 Administrative expenses –509 –385 –982 –794 –1,680 Other operating income 24 17 42 25 54 Other operating expenses 7 –45 –1 –66 –117 Operating profit (EBIT) 349 249 659 487 1,009 Financial income 60 –8 154 159 222 Financial expenses –124 –69 –272 –339 –572 Profit before tax 284 172 541 306 659 Income tax –59 –39 –119 –78 –149 Profit for the period 225 133 422 228 510 Profit attributable to: Parent Company’s shareholders 219 129 412 220 492 Non-controlling interests 6 4 11 8 18 Earnings per share before and after dilution (SEK) 5 0.57 0.34 1.07 0.54 1.25
Page 11
#11 ASKER HEALTHCARE GROUP INTERIM REPORT – Q2 2026 START CEO’S COMMENTS FINANCIAL STATEMENTS DEFINITIONS ABOUT ASKER FINANCIAL OVERVIEW Condensed consolidated statement of comprehensive income 1 April–30 June 1 January–30 June Full-year Amounts in SEKm 2026 2025 2026 2025 2025 Profit for the period 225 133 422 228 510 Other comprehensive income for the period Items that have been or can be reclassified to the income statement Translation differences for the period on translation of foreign operations 69 53 153 –167 –276 T otal other comprehensive income for the period 69 53 153 –167 –276 Comprehensive income for the period 295 186 576 60 234 Of which, attributable to: Parent Company’s shareholders 288 182 565 53 216 Non-controlling interests 6 4 11 8 18
Page 12
#12 ASKER HEALTHCARE GROUP INTERIM REPORT – Q2 2026 START CEO’S COMMENTS FINANCIAL STATEMENTS DEFINITIONS ABOUT ASKER FINANCIAL OVERVIEW Condensed consolidated balance sheet 30 June 31 December Amounts in SEKm Note 2026 2025 2025 ASSETS Goodwill 6,758 5,651 6,369 Other intangible assets 3,274 2,374 3,027 Tangible assets 1,877 1,474 1,780 Financial non-current assets 42 28 32 Deferred tax assets 86 83 94 T otal non-current assets 12,037 9,610 11,302 Inventories 2,364 1,938 2,041 Accounts receivable 2,096 1,810 2,052 Other current receivables 557 525 495 Cash and cash equivalents 777 1,325 884 T otal current assets 5,794 5,598 5,472 TOTAL ASSETS 17,832 15,208 16,774 EQUITY AND LIABILITIES Equity attributable to Parent Company’s shareholders 6,978 6,386 6,555 Non-controlling interests 41 38 33 T otal equity 7,018 6,424 6,588 Interest-bearing liabilities 3 4,256 3,361 4,224 Lease liabilities 728 654 727 Deferred tax liabilities 676 470 606 Other non-current liabilities and provisions 3 714 398 591 T otal non-current liabilities 6,374 4,883 6,149 Interest-bearing liabilities 3 1,148 850 557 Lease liabilities 344 243 306 Accounts payable 1,672 1,348 1,610 Other current liabilities 3 1,274 1,460 1,565 T otal current liabilities 4,439 3,901 4,038 TOTAL EQUITY AND LIABILITIES 17,832 15,208 16,774
Page 13
#13 ASKER HEALTHCARE GROUP INTERIM REPORT – Q2 2026 START CEO’S COMMENTS FINANCIAL STATEMENTS DEFINITIONS ABOUT ASKER FINANCIAL OVERVIEW Condensed consolidated statement of changes in equity 30 June 31 December Amounts in SEKm 2026 2025 2025 Opening balance 6,588 3,502 3,502 Comprehensive income for the period 576 60 234 Paid share issue* – 1,426 1,426 Set-off issue* – 1,439 1,439 Investment share programme 6 – 4 Dividends paid to Parent Company’s shareholders –149 – – Dividends paid to non-controlling interests –2 –1 –15 Transactions attributable to non-controlling interests – –1 –1 Closing balance 7,018 6,424 6,588 Equity attributable to: Parent Company’s shareholders 6,978 6,386 6,555 Non-controlling interests 41 38 33 * In conjunction with the IPO on 27 March 2025, Asker conducted a new share issue totalling SEK 1,500m, consisting of 21,428,571 shares at a subscription price of SEK 70 per share. Transaction costs for the full-year amounted to SEK 93m, which, net of tax, impacted equity in the amount of SEK 1,426m. In parallel, a directed set-off issue was conducted to repay existing shareholder loans. The value of shareholder loans with accrued interest amounted to SEK 1,439m, meaning that 20,552,600 new shares were issued at a subscription price of SEK 70 per share.
Page 14
#14 ASKER HEALTHCARE GROUP INTERIM REPORT – Q2 2026 START CEO’S COMMENTS FINANCIAL STATEMENTS DEFINITIONS ABOUT ASKER FINANCIAL OVERVIEW Condensed consolidated statement of cash flows 1 April–30 June 1 January–30 June Full-year Amounts in SEKm Note 2026 2025 2026 2025 2025 Operating profit (EBIT) 349 249 659 487 1,009 Adjustments for non-cash items* 235 204 474 391 839 Interest received 4 3 5 5 10 Interest paid –59 –43 –115 –102 –201 Income tax paid –83 –54 –145 –185 –337 446 359 879 595 1,321 Change in current receivables 156 –55 106 –69 –87 Change in inventories –132 –28 –137 –41 53 Change in current liabilities 4 –378 –65 –337 –165 41 Cash flow from operating activities 92 211 511 320 1,328 Investments in intangible and tangible assets –112 –206 –212 –278 –590 Sale of intangible and tangible assets 43 – 47 – 15 Acquisition of subsidiaries (less acquired cash) 4 –354 –164 –522 –997 –2,331 Cash flow from investing activities –422 –370 –687 –1,275 –2,906 New borrowings – – – 4,104 5,098 Repayments of borrowings – – – –4,037 –4,258 Repayment of lease liabilities –91 –67 –174 –134 –290 Changes in overdraft facilities 389 817 368 445 59 Share issue** – –18 1,407 1,407 Private placement for non-controlling interests – – – 24 24 Dividends paid to Parent Company’s shareholders –149 – –149 – – Dividends paid to holders of non-controlling interests –2 – –2 –1 –15 Cash flow from financing activities 146 731 43 1,808 2,025 Cash flow for the period –183 572 –132 854 447 Cash and cash equivalents at the beginning of the period 945 735 884 490 490 Exchange rate differences in cash and cash equivalents 15 18 26 –19 –53 Cash and cash equivalents at the end of the period 777 1,325 777 1,325 884 * Pertains mainly to amortisation and revaluation of contingent considerations. ** The negative cash flow impact from the share issue in the second quarter of 2025 comprised final bank fees related to the IPO.
Page 15
#15 ASKER HEALTHCARE GROUP INTERIM REPORT – Q2 2026 START CEO’S COMMENTS FINANCIAL STATEMENTS DEFINITIONS ABOUT ASKER FINANCIAL OVERVIEW Condensed income statement for the Parent Company 1 April–30 June 1 January–30 June Full-year Amounts in SEKm 2026 2025 2026 2025 2025 Net sales 8 7 11 11 19 Gross profit 8 7 11 11 19 Administrative expenses –11 –19 –23 –42 –53 Other operating income and expenses – 0 0 1 1 Operating loss –3 –12 –12 –31 –34 Financial income and expenses –3 –8 –3 34 67 Appropriations 0 0 0 0 43 Profit/loss before tax –6 –20 –15 3 76 Income tax –2 0 0 0 –19 Profit/loss for the period –8 –20 –15 3 58 The Parent Company has no transactions to report in other comprehensive income, and subsequently the Parent Company’s comprehensive income is consistent with profit/ loss for the period.
Page 16
#16 ASKER HEALTHCARE GROUP INTERIM REPORT – Q2 2026 START CEO’S COMMENTS FINANCIAL STATEMENTS DEFINITIONS ABOUT ASKER FINANCIAL OVERVIEW Condensed balance sheet for the Parent Company 30 June 31 December Amounts in SEKm 2026 2025 2025 ASSETS Financial non-current assets 3,585 3,573 3,578 T otal non-current assets 3,585 3,573 3,578 Current assets 4,021 4,241 4,176 Cash and cash equivalents 1 0 0 T otal current assets 4,022 4,241 4,176 TOTAL ASSETS 7,607 7,814 7,754 EQUITY AND LIABILITIES Restricted equity 1 1 1 Non-restricted equity 4,312 4,411 4,470 T otal equity 4,312 4,412 4,470 Untaxed reserves – 91 – Provisions 12 10 11 Non-current liabilities 3,243 3,252 3,188 Current liabilities 39 50 84 T otal liabilities 3,282 3,302 3,273 TOTAL EQUITY AND LIABILITIES 7,607 7,814 7,754
Page 17
#17 ASKER HEALTHCARE GROUP INTERIM REPORT – Q2 2026 START CEO’S COMMENTS FINANCIAL STATEMENTS DEFINITIONS ABOUT ASKER FINANCIAL OVERVIEW Notes NOTE 1 Segment information 1 April–30 June 1 January–30 June Full-year Amounts in SEKm 2026 2025 2026 2025 2025 Net sales from external customers North 1,429 1,265 2,783 2,527 5,210 West 2,327 2,021 4,580 4,029 8,543 Central 931 701 1,844 1,426 3,034 Other and eliminations – – – – – T otal net sales from external customers 4,686 3,987 9,207 7,982 16,787 Net sales from other operating segments North 21 23 43 47 93 West 25 15 43 27 72 Central 3 2 7 4 11 Other and eliminations –49 –40 –93 –77 –175 T otal net sales from other operating segments – – – – – T otal net sales 4,686 3,987 9,207 7,982 16,787 Adjusted EBITA North 193 175 379 352 681 West 224 169 438 330 757 Central 90 57 170 112 259 Other and eliminations –36 –24 –74 –52 –102 T otal adjusted EBITA 471 378 912 742 1,594 Items affecting comparability (see definitions and Note 5) 4 –55 –9 –108 –204 EBITA North 195 192 374 330 625 West 231 169 445 335 743 Central 87 3 159 67 185 Other and eliminations –37 –40 –75 –97 –163 T otal EBITA 475 323 903 634 1,390 Amortisation of intangible assets –126 –74 –245 –148 –381 Operating profit (EBIT) 349 249 659 487 1,009 Net financial items –65 –77 –118 –181 –350 Profit before tax 284 172 541 306 659
Page 18
#18 ASKER HEALTHCARE GROUP INTERIM REPORT – Q2 2026 START CEO’S COMMENTS FINANCIAL STATEMENTS DEFINITIONS ABOUT ASKER FINANCIAL OVERVIEW NOTE 2 Net sales Asker’s companies primarily sell medical supplies, devices, equipment and related services, where some equipment requires installation. Two performance obligations have been identified in customer contracts comprising delivery of medical equipment that includes installation, since both the equipment and the installation are deemed to be distinct performance obligations. The performance obligation for the sale of medical NOTE 3 Fair value of financial instruments Asker’s financial assets and financial liabilities measured at fair value through profit or loss refer to derivatives and liabilities related to contingent considerations arising in connection with acquisitions. For derivatives, the fair value is determined based on observable market data, meaning level 2 of the fair value hierarchy stipulated in IFRS 13. The closing balance for positive derivatives amounted to SEK 28m (7), and the closing balance for negative derivatives amounted to SEK 5m (34). Liabilities for contingent considerations are recognised based on the acquired company’s earnings, meaning a multiple valuation based on future EBITDA or EBITA performance measures, dis- counted using the Group’s discount rate, with future EBITDA/ Contingent consideration 30 June 31 December Amounts in SEKm 2026 2025 2025 Opening balance 870 688 688 Acquisitions 177 79 215 Payments –463 –156 –166 Remeasurement* –14 56 96 Discount effect* 38 24 61 Reclassifications – – 8 Exchange rate differences 36 –16 –32 Closing balance 645 674 870 *The earnings effect of the remeasurement of contingent considerations amounts to SEK 14m (–56) and is recognised in other operating expenses. The impact of the discount effect is SEK –38m (–24) and is recog- nised in net financial items. 1 April–30 June 1 January–30 June Full-year Amounts in SEKm 2026 2025 2026 2025 2025 Sale of goods North 1,288 1,136 2,510 2,274 4,697 West 2,123 1,986 4,178 3,495 7,855 Central 848 666 1,679 1,360 2,670 T otal goods 4,260 3,657 8,367 7,129 15,223 Sale of services North 140 128 273 253 512 West 204 34 402 534 688 Central 82 35 165 66 364 T otal services 427 329 840 853 1,564 T otal net sales 4,686 3,987 9,207 7,982 16,787 supplies, devices and equipment is satisfied when Asker’s companies deliver the supplies and equipment in accordance with the delivery terms in the specific contract and control is thus transferred to the customer. Installation of medical equipment is a service that is recognised over time as it is performed. The same applies for service contracts. EBITA measures obtained from company management’s best estimates based on adopted business plans, implying valuation in level 3 according to the fair value hierarchy. There were no transfers between levels during the period. Other assets and liabilities are recognised at amortised cost. The fair value of liabilities to credit institutions is estimated to be consistent with the carrying amount since the loans carry variable interest rates. The fair value of short-term borrowing corresponds to its carrying amount since the discount effect is not material. See below for a table of the changes in contingent considerations in level 3, from both business combinations and asset acquisi- tions.
Page 19
#19 ASKER HEALTHCARE GROUP INTERIM REPORT – Q2 2026 START CEO’S COMMENTS FINANCIAL STATEMENTS DEFINITIONS ABOUT ASKER FINANCIAL OVERVIEW As part of Asker’s value creation, whereby organic growth is complemented with acquisitions of small and medium-sized companies to add new products, customer groups and/or chan- nels and thus build a full-service offering and create a platform for a more efficient value chain for the healthcare sector, the following business combinations have been completed in 2026. • On 2 February, the Group acquired 100% of the shares in Van Heek Medical (signed in the fourth quarter of 2025), a leading manufacturer and distributor of medical supplies in the Benelux region. The company had 64 employees and a sales of approximately SEK 350m in the most recent financial year. Identified excess values consist of customer relationships, trademarks and goodwill. • On 3 February, the Group acquired 100% of the shares in German Healthcare (GHC) and Medicalprodukte Vertrieb Flensburg (MPF), two interlinked medical supplies companies within the home care segment in Germany. The companies had 140 employees and sales of approximately SEK 300m in the most recent financial year. Identified excess values con- sist of customer relationships, trademarks and goodwill. • On 1 April, the Group acquired 100% of the shares in RMS Medical Devices, a fast-growing medical device distributor based in Belgium. The company had 25 employees and sales of approximately SEK 170m in the most recent financial year. Identified excess values consist of customer relationships, trademarks and goodwill. • In June, it was decided that the Group would discontinue the acquisition of Kirstine Hardam in Denmark, which had been announced in June 2025, in full agreement with the company’s owner. Preliminary purchase price allocations for acquired identifiable net assets are provided below. Since individual disclosures about acquisitions are not material, disclosures are provided in aggregated form. Acquired assets measured at fair value Amounts in SEKm T otal for the period Intangible assets 346 Tangible assets 9 Right-of-use assets 55 Inventories 136 Other current assets 160 Cash and cash equivalents 32 Deferred tax assets/liabilities –88 Interest-bearing liabilities –60 Lease liabilities –55 Other operating liabilities –107 T otal identifiable net assets 428 Goodwill 266 Non-controlling interests – Consideration 693 Paid consideration 328 Outstanding consideration 2026 187 Contingent consideration 177 T otal estimated consideration 693 NOTE 4 Business combinations Effect of acquisitions on cash flow Amounts in SEKm T otal for the period Paid consideration –328 Cash and cash equivalents in acquired companies 32 Paid contingent consideration impacting investing activities* –226 T otal cash flows in investing activities –522 Paid contingent consideration impacting operating activities* –238 T otal cash flow from operating activities –238 * According to IFRS accounting policies, payments of contingent considerations must be allocated in the statement of cash flows between financing activities and operating activities based on how they have impacted initial purchase price allocations and earnings, respectively, in subsequent periods. Other current assets mainly relate to accounts receivable. There is no material difference between acquired receivables and the gross amount, and there are no receivables that are not expected to be settled. Control was obtained through initial cash payments, forthcoming settlements of purchase considerations related to completed acquisitions, and contin- gent consideration agreements. Asker prepares preliminary purchase price allocations for the period during which there is uncertainty regarding the outcome of specific components of the acquisition agreements, for example, during the period that the company engages external valuation specialists and the external valuation has not yet been completed, or in cases when the final acquisition balance has not been received. However, the valuation period never extends for more than one year from the acquisition date. The purchase price allocations for acquisitions completed as of the third quarter of 2025 up to and including the second quarter of 2026 are preliminary since the Group has not received final, definitive information from the acquired companies. No material changes were made to the Group’s purchase price allocations during the quarter with respect to acquisitions in the prior year. Fair value adjustments to intangible assets generally com- prise customer relationships, customer contracts and trade- marks. Goodwill is justified based on high profitability and the personnel included in the acquired companies. For acquisi- tions, Asker usually applies an acquisition structure with basic consideration and possible contingent consideration. The con- tingent consideration is based on the earnings of the acquiree, implying a multiple valuation based on future EBITDA or EBITA performance measures, discounted using the Group’s dis- count rate. Future EBITDA/EBITA performance measures are obtained from management’s best estimate based on adopted business plans. Contingent consideration is initially measured at the present value of probable future outcomes, which for the acquisitions during the period has been estimated at SEK 177m (72). In total, contingent considerations for acquisitions com- pleted during the period may amount to between SEK 0m and SEK 533m. No changes were made to the method for calculat- ing consideration. Transaction costs for the acquisitions made during the period amounted to SEK 5m (22) and are included in administrative expenses in profit or loss. The impact on the Group’s net sales from the acquired companies since the acquisition date amounted to SEK 273m and the impact on the Group’s EBITA since the acquisition date amounted to SEK 47m. If all acquired companies had been consolidated from 1 January 2026, net sales for the period would have amounted to SEK 9,303m and EBITA to SEK 911m.
Page 20
#20 ASKER HEALTHCARE GROUP INTERIM REPORT – Q2 2026 START CEO’S COMMENTS FINANCIAL STATEMENTS DEFINITIONS ABOUT ASKER FINANCIAL OVERVIEW NOTE 4 Business combinations, cont. Acquisitions in the last two years Y ear Month of closure Acquisitions Business area Country Acquired shareholding Net sales*, SEKm No. of full-time equivalents 2026 April RMS West Netherlands 100% 170 19 2026 February GHC/MPF Central Germany 100% 300 117 2026 February Van Heek Medical West Netherlands 100% 350 59 2025 December Cardio Dépôt Central France 100% 25 5 2025 November InnoMedicus Central Switzerland 100% 50 10 2025 October Novus Med West UK 100% 80 12 2025 October Finmed Central France 79% 380 62 2025 October Dartin Central Czech Republic 100% 46 23 2025 September Oudshoorn West Netherlands 100% 37 8 2025 August HNC West UK 100% 60 19 2025 July Scan Modul West Netherlands 100% 400 94 2025 July ITAK North Estonia 100% 90 67 2025 May MS Labors Central Austria 100% 23 5 2025 February HSL Group West Ireland 97% 800 150 2025 February Mayumana West Netherlands 100% 60 11 2024 November Hauser Central Austria 100% 23 5 2024 November Opitek West Denmark 100% 10 3 2024 October Kvinto North Norway 100% 60 3 2024 September Hugo Central UK 100% 81 84 2024 August Aspironix Central Czech Republic 100% 200 70 2024 August meetB Central Germany 100% 340 60 2024 August Funktionsverket North Sweden 100% 30 2 2024 July Wolturnus West Denmark 100% 150 71 * Estimated net sales at date of acquisition, annual basis Completed acquisitions after the end of the reporting period • On 3 July, the Group acquired 100% of the shares in Murray Surgical Limited, a leading distributor of specialist surgical and medical products to the healthcare sector in Ireland. The company had nine employees and sales of approximately SEK 73m in the most recent financial year. The purchase price allocation is ongoing and excess values are expected to consist of customer relationships and goodwill.
Page 21
#21 ASKER HEALTHCARE GROUP INTERIM REPORT – Q2 2026 START CEO’S COMMENTS FINANCIAL STATEMENTS DEFINITIONS ABOUT ASKER FINANCIAL OVERVIEW Adjusted EBITA and adjusted EBITA margin, % 1 April–30 June 1 January–30 June Rolling 12 months Full-year Amounts in SEKm 2026 2025 2026 2025 2025/2026 2025 Operating profit (EBIT) 349 249 659 487 1,181 1,009 Amortisation of intangible assets from acquisitions 96 56 186 111 363 288 Amortisation of intangible assets from operating activities 30 18 59 37 115 93 EBITA 475 323 903 634 1,659 1,390 Items affecting comparability Acquisition and integration expenses 9 15 20 37 73 90 Revaluation of contingent considerations –17 39 –14 56 27 96 Other non-recurring items 3 1 4 15 7 18 T otal items affecting comparability –4 55 9 108 106 204 Adjusted EBITA 471 378 912 742 1,765 1,594 Net sales 4,686 3,987 9,207 7,982 18,012 16,787 Adjusted EBITA margin, % (Adjusted EBITA/Net sales) 10.0% 9.5% 9.9% 9.3% 9.8% 9.5% EBITA growth Rolling 12 months Full-year Amounts in SEKm 2025/2026 2025 Adjusted EBITA 1,765 1,594 Growth, current period compared with previous 21.3% 17.1% EBITA margin 1 April–30 June 1 January–30 June Rolling 12 months Full-year Amounts in SEKm 2026 2025 2026 2025 2025/2026 2025 EBITA 475 323 903 634 1,659 1,390 Net sales 4,686 3,987 9,207 7,982 18,012 16,787 EBITA margin 10.1% 8.1% 9.8% 7.9% 9.2% 8.3% Adj. cash flow from operating activities 1 April–30 June 1 January–30 June Full-year Amounts in SEKm 2026 2025 2026 2025 2025 Cash flow from operating activities 92 211 511 320 1,328 Payment of contingent considerations that impacted operating activities 238 – 238 – 57 Adj. cash flow from operating activities 330 211 749 320 1,385 NOTE 5 Alternative performance measures Certain information in Asker’s interim report that is used by management and analysts to assess and evaluate the Group’s financial position and earnings is not defined in accordance with IFRS Accounting Standards. The Group believes that the information aids the understanding of Asker’s financial position and earnings. This information should be regarded as supple- mentary information and does not replace the consolidated financial statements prepared in accordance with IFRS.
Page 22
#22 ASKER HEALTHCARE GROUP INTERIM REPORT – Q2 2026 START CEO’S COMMENTS FINANCIAL STATEMENTS DEFINITIONS ABOUT ASKER FINANCIAL OVERVIEW EBITDA adjusted for leases and items affecting comparability 1 April–30 June 1 January–30 June Rolling 12 months Full-year Amounts in SEKm 2026 2025 2026 2025 2025/2026 2025 Operating profit (EBIT) 349 249 659 487 1,181 1,009 Depreciation of tangible assets 130 101 251 198 488 435 Amortisation of intangible assets from acquisitions 96 56 186 111 363 288 Amortisation of intangible assets from operating activities 30 18 59 37 115 93 Operating profit (EBITDA) 605 424 1,154 832 2,147 1,825 Items affecting comparability –4 55 9 108 106 204 Expenses attributable to leases –97 –71 –191 –142 –354 –305 EBITDA adjusted for leases and items affecting comparability 503 408 972 798 1,900 1,724 Net debt 30 June 31 December Amounts in SEKm 2026 2025 2025 Non-current interest-bearing liabilities 4,256 3,361 4,223 Non-current interest-bearing liabilities to credit institutions 4,256 3,361 4,223 Current interest-bearing liabilities 1,033 850 557 Current interest-bearing liabilities to credit institutions 1,033 850 557 Cash and cash equivalents 777 1,325 884 Net debt 4,511 2,886 3,896 Debt/equity ratio 30 June 31 December Amounts in SEKm 2026 2025 2025 Net debt 4,511 2,886 3,896 Total equity 7,018 6,424 6,588 Debt/equity ratio 0.6 0.4 0.6 Net debt/EBITDA adjusted for leases and items affecting comparability 30 June 31 December Amounts in SEKm 2026 2025 2025 Net debt 4,511 2,886 3,896 EBITDA adjusted for leases and items affecting comparability, rolling 12 months 1,900 1,565 1,724 Net debt/EBITDA adjusted for leases and items affecting comparability 2.37 1.84 2.26 Capital employed 30 June 31 December Amounts in SEKm 2026 2025 2025 Total equity 7,018 6,424 6,588 Total interest-bearing liabilities 5,404 4,211 4,781 Contingent considerations 645 674 870 Compound call and put option 133 115 127 Total lease liabilities 1,073 897 1,033 T otal capital employed 14,273 12,321 13,399 NOTE 5 Alternative performance measures, cont.
Page 23
#23 ASKER HEALTHCARE GROUP INTERIM REPORT – Q2 2026 START CEO’S COMMENTS FINANCIAL STATEMENTS DEFINITIONS ABOUT ASKER FINANCIAL OVERVIEW NOTE 5 Alternative performance measures, cont. Return on capital employed 30 June 31 December Amounts in SEKm 2026 2025 2025 Operating profit (EBIT), rolling 12 months 1,181 986 1,009 Average capital employed 13,632 10,946 12,456 Return on capital employed, % 8.7% 9.0% 8.1% Goodwill from owner change 2019 –2,493 –2,493 –2,493 Adjusted average capital employed 11,139 8,453 9,963 Return on adjusted capital employed, % 10.6% 11.7% 10.1% Net working capital 30 June 31 December Amounts in SEKm 2026 2025 2025 Inventories 2,364 1,938 2,041 Accounts receivable 2,096 1,810 2,052 Accounts payable –1,672 –1,348 -1,610 Advance payments from customers –21 –20 -25 T otal net working capital 2,767 2,380 2,459 Return on net working capital (EBITA/NWC), % 30 June 31 December Amounts in SEKm 2026 2025 2025 Adjusted EBITA, rolling 12 months 1,765 1,454 1,594 Average net working capital 2,567 2,225 2,378 Return on net working capital (EBITA/NWC), % 68.7% 65.4% 67.0% Earnings per share Asker has calculated earnings per share in accordance with IAS 33, whereby profit attributable to the Parent Company has been adjusted for the interest component of preference shares, with adjustment being made for the number of common shares received after the conversion of preference shares to common shares in conjunction with the IPO, and the number of shares has been calculated based on the basis of the average number of shares outstanding. As an alternative performance measure, Asker has calculated earnings per share based on recognised profit or loss for the period, and as if the effects of the new share issue, the set-off issue and the conversion of preference shares to common shares had taken place before the start of the initial comparative period. 1 April–30 June 1 January–30 June Rolling 12 months Full-year 2026 2025 2026 2025 2025/2026 2025 Profit or loss attributable to Parent Company’s shareholders (SEKm) 219 129 412 220 683 492 Adjustment for interest component of preference shares (SEKm) – – – –31 – –31 Adjusted profit or loss attributable to Parent Company’s shareholders (SEKm) 219 129 412 189 683 461 Average number of common shares outstanding 383,036,497 383,036,497 383,036,497 353,294,482 383,036,497 368,248,106 Earnings per share (SEK) 0.57 0.34 1.07 0.54 1.78 1.25 Profit or loss attributable to Parent Company’s shareholders (SEKm) 219 129 412 220 683 492 Total number of common shares outstanding 383,036,497 383,036,497 383,036,497 383,036,497 383,036,497 383,036,497 Adjusted earnings per share (SEK) 0.57 0.34 1.07 0.57 1.78 1.28
Page 24
#24 ASKER HEALTHCARE GROUP INTERIM REPORT – Q2 2026 START CEO’S COMMENTS FINANCIAL STATEMENTS DEFINITIONS ABOUT ASKER FINANCIAL OVERVIEW Financial key performance indicators 2026 2025 2024 Amounts in SEKm unless otherwise stated Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Net sales 4,686 4,521 4,676 4,129 3,987 3,995 4,303 3,597 3,669 EBITA 475 428 407 348 323 311 359 272 326 EBITA margin, % 10.1% 9.5% 8.7% 8.4% 8.1% 7.8% 8.3% 7.6% 8.9% Adjusted EBITA 471 442 470 383 378 364 406 306 338 Adjusted EBITA margin, % 10.0% 9.8% 10.0% 9.3% 9.5% 9.1% 9.4% 8.5% 9.2% EBITDA adjusted for leases and items affecting comparability 503 469 511 417 408 389 433 335 364 Capital employed 14,273 14,074 13,399 12,780 12,321 11,324 10,247 9,894 9,169 Average capital employed 13,632 13,143 12,456 11,668 10,946 10,158 9,615 9,211 8,901 EBIT 349 310 281 242 249 237 287 212 271 Return on capital employed, % 8.7% 8.2% 8.1% 8.7% 9.0% 9.9% 10.0% 8.2% 7.5% Return on adjusted capital employed, % 10.6% 10.2% 10.1% 11.1% 11.7% 13.2% 13.6% 11.2% 10.5% Total assets 17,832 17,753 16,774 15,937 15,208 14,234 13,118 12,631 11,825 Equity 7,018 6,871 6,588 6,509 6,424 6,239 3,502 3,356 3,297 Profit for the period 225 197 136 146 133 95 108 82 117 Net debt 4,511 3,871 3,896 3,648 2,886 2,585 3,091 3,113 2,702 Net debt/EBITDA adjusted for leases and items affecting comparability 2.4 2.1 2.3 2.2 1.8 1.7 2.1 2.2 2.1 Debt/equity ratio 0.6 0.6 0.6 0.6 0.4 0.4 0.9 0.9 0.8 Net working capital 2,767 2,619 2,459 2,425 2,380 2,250 2,157 2,112 1,982 Average net working capital 2,567 2,470 2,378 2,303 2,225 2,125 2,020 1,917 1,846 Return on net working capital (EBITA/NWC), % 68.7% 67.7% 67.0% 66.5% 65.4% 66.5% 67.4% 66.3% 65.6% Adjusted cash flow from operating activities 330 419 568 439 211 109 459 223 308 1 January–30 June Rolling 12 months Full-year Amounts in SEKm unless otherwise stated 2026 2025 2025/2026 2025 Net sales 9,207 7,982 18,012 16,787 EBITA 903 634 1,659 1,390 EBITA margin, % 9.8% 7.9% 9.2% 8.3% Adjusted EBITA 912 742 1,765 1,594 Adjusted EBITA margin, % 9.9% 9.3% 9.8% 9.5% EBITDA adjusted for leases and items affecting comparability 972 798 1,900 1,724 Average capital employed 13,632 10,946 13,631 12,456 Return on capital employed, % 8.7% 9.0% 8.7% 8.1% Net debt 4,511 2,886 4,511 3,896 Net debt/EBITDA adjusted for leases and items affecting comparability 2.4 1.8 2.4 2.3 Debt/equity ratio 0.6 0.4 0.6 0.6 Average net working capital 2,567 2,225 2,567 2,378 Return on net working capital (EBITA/NWC), % 68.7% 65.4% 68.7% 67.0% Average number of full-time equivalents 4,053 3,560 3,937 3,695 Number of employees at the end of the period 4,885 4,248 4,885 4,559 Adjusted cash flow from operating activities 749 320 1,814 1,385 Earnings per share before and after dilution (SEK) 1.07 0.54 1.78 1.25 Earnings per share before and after dilution (SEK), adjusted* 1.07 0.57 1.78 1.28 * Refer to Note 5 for the calculation of alternative performance measures.
Page 25
#25 ASKER HEALTHCARE GROUP INTERIM REPORT – Q2 2026 START CEO’S COMMENTS FINANCIAL STATEMENTS DEFINITIONS ABOUT ASKER FINANCIAL OVERVIEW Definitions KEY PERFORMANCE INDICATORS DEFINITIONS PURPOSE EBITA Operating profit before amortisation and impairment of intangible assets. EBITA provides an overall view of profit generated by op- erations and is a metric that the Group considers to be relevant for investors who want to understand earnings generation before amortisation of intangible assets. EBITA margin, % EBITA as a percentage of net sales. The KPI is used to measure the company’s profitability before amortisation and impairment of intangible assets. Items affecting comparability Acquisition and integration expenses, revaluation of contingent considerations, as well as other non-recurring items deemed to affect comparability. Items affecting comparability make adjustments for items that are not deemed to reflect the underlying operations. Adjusted EBITA EBITA excluding items affecting comparability. The KPI increases comparability of EBITA over time since it makes adjustments for the impact of items affecting comparability that are considered to be of a non-recurring nature and therefore do not reflect the underlying operations. Adjusted EBITA margin, % Adjusted EBITA as a percentage of net sales. The KPI is used to measure the company’s profitability excluding the impact of acquisition and integration ex- penses and other items affecting comparability. Organic growth Year-on-year change in net sales or profit/loss, excluding exchange rate effects, from entities that have been part of the Group for at least 12 months. Growth that arises when Group companies take over specific assets (asset acquisitions) from other operators is normally considered organic growth. This could take the form of the Group taking over distribution contracts and paying a compen- sation fee to a previous operator. Organic growth is used to illustrate growth from the underlying business operations adjusted for the effects of currency and acquisitions. EBITA growth Percentage change in EBITA between two periods. The KPI is used to measure the company’s earnings growth. EBITDA adjusted for leases and items affecting comparability Operating profit before depreciation, amortisation and impairment of tangible and intangible assets less actual rent costs attributable to leases and items affecting comparability. The metric shows the company’s earnings generation before investments in non-current assets as if all leases had been recognised as operating leases and adjusted for acquisition and integration expenses and other items affecting comparability. Adjusted cash flow from operating activities Cash flow from operating activities, adjusted for pay- ments of contingent considerations that, under IFRS Accounting Standards, must be presented under operat- ing activities in the statement of cash flows. This metric shows the company’s underlying cash flow from operating activities. Capital employed Equity and interest-bearing liabilities including contingent considerations and liabilities related to compound call and put options. Capital employed is a metric that the Group considers to be relevant for investors who want to understand the company’s net assets that are to generate profit. Adjusted capital employed Equity and interest-bearing liabilities including contingent considerations and liabilities related to combined call and put options less the goodwill arising from the change of ownership in 2019. The metric adjusts capital employed by the goodwill that arose from the change of ownership in 2019 to better reflect the capital of the underlying operations. Average capital employed/ adjusted capital employed Average capital employed/adjusted capital employed for the four most recent quarters. The measure provides an understanding of capital em- ployed/adjusted capital employed over time and is used to calculate the return on capital employed. Return on capital employed/ adjusted capital employed, % Operating profit (EBIT) rolling 12 months as a percentage of average capital employed/adjusted capital employed. The metric is an indication of how efficient the Group is at utilising its capital resources. Net debt Non-current and current interest-bearing liabilities to credit institutions less cash and cash equivalents. This KPI is used as a supplement to assess the feasibility of paying dividends and making strategic investments, and for assessing the Group’s ability to meet its financial commitments. Net debt/EBITDA adjusted for leases and items affecting comparability Net debt as a percentage of EBITDA less actual rent costs attributable to leases and items affecting compara- bility, rolling 12 months. This KPI is a debt ratio that shows how many years it would take to pay off the company’s debt, provided that its net debt and EBITDA are constant and without taking into account cash flows for interest, tax and investments. Debt/equity ratio Net debt as a percentage of equity. The metric shows the proportion of net debt as a per- centage of equity. Net working capital Total of inventories and accounts receivable less ac- counts payable and advance payments from customers. This metric shows the capital that the company has available to finance the operating activities.
Page 26
#26 ASKER HEALTHCARE GROUP INTERIM REPORT – Q2 2026 START CEO’S COMMENTS FINANCIAL STATEMENTS DEFINITIONS ABOUT ASKER FINANCIAL OVERVIEW KEY PERFORMANCE INDICATORS DEFINITIONS PURPOSE Average net working capital Total of inventories and accounts receivable less ac- counts payable and advance payments from customers, average for the four most recent quarters. The measure provides an understanding of working capital over time and is used to calculate the return on net working capital. Return on net working capital (EBITA/NWC), % Adjusted EBITA rolling 12 months as a percentage of average net working capital. The KPI is used to analyse profitability and is a metric that puts a premium on high EBITA and low net working capital requirements. Cash flow from operating activities Total of cash flow for the period from operating activities. Cash flow is used to provide an overview of the cash and cash equivalents that flow in and out of the operations. Average number of full-time equivalents Calculated as the average number of employees for the year, taking into account the percentage of full-time employment. The metric can be used to compare specific key perfor- mance indicators in relation to average employees. Number of employees at the end of the period The number of employees in the Group at the end of the period. This metric is used to know how many employees the Group has at the end of a given period. Earnings per share Profit for the period, adjusted for the amount related to the settlement of preference shares, attributable to the Parent Company’s shareholders divided by the average number of common shares outstanding. Earnings per share is used to determine the value of the company’s average number of common shares outstanding. Adjusted earnings per share Recognised profit for the period attributable to the Parent Company’s shareholders divided by the total number of common shares outstanding. Adjusted earnings per share is used to determine the value of the company’s total number of common shares outstanding.
Page 27
ASKER HEALTHCARE GROUP INTERIM REPORT – Q2 2026 START CEO’S COMMENTS FINANCIAL STATEMENTS DEFINITIONS ABOUT ASKER FINANCIAL OVERVIEW Address: Asker Healthcare Group AB Svärdvägen 3A, SE-182 33 Danderyd, Sweden www.asker.com About Asker Healthcare Group Financial calendar Date Interim Report – Q3 2026 4 November 2026 Year-end report 10 February 2027 Additional information Investors and analysts Thomas Moss, CFO and Head of IR Tel: +46 70 219 79 05 E-mail: ir@asker.com Media Emma Rheborg, Head of Communication Tel: +46 73 313 62 17 E-mail: emma.rheborg@asker.com This information is such information that Asker Healthcare Group AB (publ) is obligated to make public pursuant to the Swedish Securities Market Act. The information was submitted for publication, through the agency of the contact persons set out above, at 8:10 a.m. CEST on 21 July 2026. Leading provider of medical products and solutions – Driving progress in the European healthcare sector. Asker Healthcare Group is a European leading provider of medical products and solutions. Over the past decade we have organically and via acquisitions built a pan-European group with deep knowledge in healthcare, attracting entrepreneurs that together with us want to drive progress and support the healthcare sector to improve patient outcomes, reduce the total cost of care and ensure a fair and sustainable value chain. By combining entrepreneurial responsibility with a distinct steering model, we have created a solid platform for growth with continuous acquisitions in the large and fragmented European market. Today, the Group consists of more than 50 companies in 19 countries and more than 5,000 employees, and brings significant scale and knowledge sharing, to the benefit of the Group and the healthcare sector. We are “Health in progress”. asker.com/sustainability/ sustainability-reporting/msci Organic growth and platform for economies of scale Acquisition motor and natural consolidation of the market Asker’s strategy for value creation – its twin engine – is built on two distinct but interlinked components that combine organic growth with acquisitions.